MapLight Therapeutics debuts on Nasdaq at $19, above $17 IPO price By Investing.com
Update: 2025-10-27
Description
MapLight Therapeutics, a biopharmaceutical company targeting central nervous system disorders, made a strong Nasdaq debut, opening above its IPO price! Fueled by a $258.9 million haul from its public offering and a private placement with Goldman Sachs affiliates, MapLight is advancing its lead therapy for schizophrenia and Alzheimer's-related psychosis through Phase 2 trials, backed by major players like Morgan Stanley and Jefferies. Will this IPO launch a breakthrough in mental health treatment?
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
